Verzenio Is Significant– Cuts The Risk of Cancer Coming Back In Some Women With Early Breast Cancer– A First For CDK4/6 Inhibitors

Updated June 29th, 2020

Verzenio Is Significant– Cuts The Risk of Cancer Coming Back In Some Women With Early Breast Cancer– A First For CDK4/6 Inhibitors

During a clinical trial, researchers found that CDK4/CDK6 inhibitor Verzenio may have a huge impact on women battling early stage breast cancer by decreasing the likelihood of the cancer returning.

NOW
PLAYING
World Health Organization Advises Women to Cut Back on Alcohol Consumption to Reduce Risk of Breast Cancer
NOW
PLAYING
New Hope For Some Early-Stage Breast Cancer Patients: FDA Approves Targeted Therapy Drug Verzenio
NOW
PLAYING
It’s National Breast Cancer Awareness Month; Here Are Four Treatment & Screening Advancements Grabbing the Attention of Oncologists
NOW
PLAYING
Does Left Breast Radiation Therapy Increase Your Risk of Heart Disease Compared to Right Breast Radiation?
NOW
PLAYING
ENHERTU Is A 'Big Game Changer' for HER2 Positive Metastatic Breast Cancer Patients
NOW
PLAYING
What is Metastatic Breast Cancer?

Treatment: Lymphedema

SEE MORE   

Treatment: Lymphedema

Lymphedema is a chronic swelling that can occur after breast cancer surgery and radiation.

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.